2022 PSC Partners Conference to be Hosted By Brigham and Women’s Hospital & Massachusetts General Hospital
We are excited to announce that PSC Partners Seeking a Cure will be hosting its…
The Resnek Family Center for PSC Research, a driving force in the quest for effective treatments for individuals living with primary sclerosing cholangitis (PSC), has recently embarked on a collaborative effort alongside leaders in the field of inflammatory diseases to understand differences and imbalances in the gut microbiomes of patients with ulcerative colitis (UC), PSC, and healthy individuals.
The [Rosetta] study, will analyze [genomic data and stool] samples collected by the Crohn’s and Colitis Foundation’s [Plexus] biorepository in addition to samples collected from the Resnek Center’s biobank. Exploring changes in the genetic makeup of the intestinal microbiome of patients and healthy individuals will hopefully provide crucial answers to the underlying cause of UC and its accompanying liver comorbidity, PSC. The study’s central aim focuses on whether increased levels of hydrogen sulfide, a [potentially] toxic gas, incite inflammation and liver injury. The study will continue into [December of 2022].
Collaborators involved: Crohn’s and Colitis Foundation, the University of California Davis, Diversigen, and Metabolon Inc.